Journal article
Small intestinal cannabinoid receptor changes following a single colonic insult with oil of mustard in mice
Frontiers in pharmacology, v 1, 132
01 Jan 2010
PMID: 21779244
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Cannabinoids are known to be clinically beneficial for control of appetite disorders and nausea/vomiting, with emerging data that they can impact other GI disorders, such as inflammation. Post-inflammatory irritable bowel syndrome (PI-IBS) is a condition of perturbed intestinal function that occurs subsequent to earlier periods of intestinal inflammation. Cannabinoid 1 receptor (CB1R) and CB2R alterations in GI inflammation have been demonstrated in both animal models and clinically, but their continuing role in the post-inflammatory period has only been implicated to date Therefore, to provide direct evidence for CBR involvement in altered GI functions in the absence of overt inflammation, we used a model of enhanced upper GI transit that persists for up to 4 weeks after a single insult by intracolonic 0.5% oil of mustard (OM) in mice. In mice administered OM, CB 1R immunostaining in the myenteric plexus was reduced at day 7 when colonic inflammation is subsiding, and then increased at 28 days, compared to tissue from age matched vehicle treated mice. In the lamina propria CB2R immunostaining density was also increased at day 28. In mice tested 28 day after OM, either a CB1R-selective agonist, ACEA (1 and 3 mg/kg, s.c.) or a CB2R-selective agonist, JWH-133 (3 and 10 mg/kg, s.c.) reduced the enhanced small intestinal transit in a dose-related manner. Doses of ACEA and JWH-133 (1 mg/kg), alone or combined, reduced small intestinal transit of OM treated mice to a greater extent than control mice. Thus, in this post-colonic inflammation model, both CBR subtypes are up-regulated and there is increased efficacy of both CB1R and CB2R agonists. We conclude that CBR remodeling occurs not only during GI inflammation but continues during the recovery phase. Thus, either CB1R- or CB2-selective agonists could be efficacious for modulating GI motility in individuals experiencing diarrhea-predominant PI-IBS.
Metrics
4 Record Views
Details
- Title
- Small intestinal cannabinoid receptor changes following a single colonic insult with oil of mustard in mice
- Creators
- Edward S. Kimball - Johnson & JohnsonNathaniel H. Wallace - Johnson & Johnson Pharmaceut Res & Dev LLC, Spring House, PA USACraig R. Schneider - Johnson & Johnson Pharmaceut Res & Dev LLC, Spring House, PA USAMichael R. D'Andrea - Johnson & Johnson Pharmaceut Res & Dev LLC, Spring House, PA USAPamela J. Hornby - Johnson & Johnson
- Publication Details
- Frontiers in pharmacology, v 1, 132
- Publisher
- Frontiers Media Sa
- Number of pages
- 8
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:000209177100030
- Other Identifier
- 991021931780304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Pharmacology & Pharmacy